The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome
Kidney International · 2025
DOI: 10.1016/j.kint.2025.04.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025. Verfasst von Alla Mitrofanova und 22 weiteren Autor:innen. Beteiligte Einrichtung: Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA; Peg…. Hauptthemen laut MEDLINE: Podocytes, Nephritis, Hereditary, Proteinuria, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Chronic kidney disease, including Alport Syndrome, is linked to collagen type IV mutations, lipid dysmetabolism, and altered sphingolipid pathways, with no targeted therapies currently available. Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b), a key regulator of sphingolipid metabolism and membrane receptor organization in podocytes, may drive disease via ceramide and sphingosine-1-phosphate pathways. This study tested whether altered SMPDL3b expression contributes to glomerular injury and renal decline in Alport Syndrome. METHODS: Archived Alport Syndrome human biopsies were used for immunohistochemistry and NanoString re-analysis of SMPDL3b. Murine podocytes isolated from mouse models of Alport Syndrome were profiled using Illumina. Mouse models of Alport Syndrome and models with either podocyte-specific deletion or inducible overexpression of Smpdl3b were generated to assess renal function using liquid chromatography-mass spectrometry, matrix-assisted laser desorption ionization-mass spectrometry imaging and atomic force microscopy. RESULTS: We found a three-fold increase in SMPDL3b expression in glomeruli, tubules and murine podocytes isolated from Col4a3 knockout mice. Increased SMPDL3b expression occurred in association with alterations affecting kidney sphingolipid metabolism, increased glomerular but not tubular sphingosine-1-phosphate levels and reduced glomerular basement membrane and podocyte stiffness. Podocyte-specific Smpdl3b deletion in Col4a3 knockout mice was sufficient to restore sphingosine-1-phosphate levels, to reduce proteinuria, podocyte foot process effacement, and improve glomerular basement membrane and podocyte stiffness, but not sufficient to protect from kidney failure. CONCLUSIONS: Our study suggests that SMPDL3b may be a key modulator of proteinuria and podocyte integrity in Alport Syndrome, decoupling proteinuria from kidney failure, and suggests that improvement of glomerular structure and function may not always translate into protection from chronic kidney disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA; Peggy and Harold Katz Family Drug Discovery Center, University of Miami,…
- Division of Nephrology, Center for Precision Medicine, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
- Division of Nephrology, Department of Medicine, Unity Health Toronto and University of Toronto, Toronto, Canada.
- Diabetes Research Institute, University of Miami, Miller School of Medicine, Miami, Florida, USA.
- Department of Pathology, University of Miami Medical Group, Miller School of Medicine, Miami, Florida, USA.
- GOFARR Laboratory, Children's Hospital Los Angeles, Division of Urology, Saban Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIA NIH HHS
- BLRD VA
- American Society of Nephrology
- American Heart Association Inc
- U.S. Department of Veterans Affairs
- National Institutes of Health
Zitieren
APA
Mitrofanova, A., Fontanella, A. M., Molina, J., Zhang, G., Mallela, S. K., Severino, L. U., Santos J, J. V., Tolerico, M., Njeim, R., Issa, W., Boulina, M., Carrazco, A., Semenova, V., Zuo, Y., Ficarella, M., Kim, J. J., Sloan, A., Sharma, K., Yuen, D. A., …, & Merscher, S. (2025). The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome. Kidney International. https://doi.org/10.1016/j.kint.2025.04.024
Vancouver
Mitrofanova A, Fontanella AM, Molina J, Zhang G, Mallela SK, Severino LU, et al. The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome. Kidney International. 2025. doi:10.1016/j.kint.2025.04.024
BibTeX
@article{Mitrofanova2025,
author = {Mitrofanova, Alla and Fontanella, Antonio M and Molina, Judith and Zhang, Guanshi and Mallela, Shamroop K and Severino, Luisa Ulloa and Santos J, Javier Varona and Tolerico, Matthew and Njeim, Rachel and Issa, Wadih and Boulina, Maria and Carrazco, Arianna and Semenova, Veronika and Zuo, Yiqin and Ficarella, Maria and Kim, Jin Ju and Sloan, Alexis and Sharma, Kumar and Yuen, Darren A and Perin, Laura and Burke, George W and Fornoni, Alessia and Merscher, Sandra},
title = {The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome},
journal = {Kidney International},
year = {2025},
doi = {10.1016/j.kint.2025.04.024}
}
EUVIMED